Nyxoah S.A

19.03.2019 – 09:01
Nyxoah Receives European CE Mark Approval for the Genio® System, a Disruptive Neurostimulation Solution for Obstructive Sleep Apnea Therapy
Mont-Saint-Guibert, Belgium (ots/PRNewswire) - Nyxoah S.A., a healthtech company focusing on the development of innovative solutions and services for sleep related disorders, today announced that the company has received CE Mark approval for the Genio® system in Europe. The Genio® system is the world's first and ...
plus
12.11.2018 – 12:01
Nyxoah Raises EUR15 Million in New Financing, Completes BLAST OSA Clinical Study
Mont-Saint-Guibert, Belgium (ots/PRNewswire) - Nyxoah S.A., a medical device company focused on the development and commercialization of a best-in-class hypoglossal nerve stimulation (HGNS) therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it successfully raised an additional EUR15 million ($17.1 million USD) in their most recent round of ...
plus